Clinical Trial Update: A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC [Phase 1, Phase 2]

View source ↗

Summary

An early-phase Phase Ib/II open-label study evaluating AMO959 in combination with Lutetium-177 vipivotide tetraxetan (AAA617) and an androgen receptor pathway i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• AMO959
• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy | Phase 1, Phase 2 | Status: RECRUITING